Sánchez HO, Zaragoza RG, Flores FJ, Jiménez VA, Sánchez-Pazarán JL, Blanco CM, Arrieta MEM, Menchi XR

Language: Spanish
References: 14
Page: 45-53
PDF size: 665.80 Kb.

ABSTRACT

Objective. To analyze short and long term evolution of patient with eluting stents. Material and methods. We review 2 group of patients that underwent percutaneous revascularization with eluting stents (TAXYS and CYPHER), to determine their clinical evolution, one group had an immediate follow up and the other group had a long term follow up (2 years), this was done in the department of homodynamic at the “20 de Noviembre National Medical Center” Results. 25 patients were evaluated in total, 11 patients with a short term follow up and 14 patients with an immediate follow up. In the first group 15 stents (CYPHER) were placed, and in the second group 21 stents were placed (19 TAXUS and 2 CYPHER). No patient of group one has required a new revascularization of the treated vessel. A follow up of group one was done in 78% of the patients, and there were no mayor cardiovascular events, death or revascularization needed. 95% of the patients had an angiography, and none of them presented in-stent restenosis. A follow-up of group two was done in all patients, finding only in two patients symptoms of recurrence (Class II CCS), but none of the patients had a myocardial infraction (MI) or the need for a revascularization. There were only two immediate complications due to the stents. Conclusions. With the use of eluting stents we corroborate what it is describe in the literature, it reduces the MI and mayor cardiovascular events incidence. Also reduces the need of revascularization and in-stent restenosis in an immediate and long term follow up.

REFERENCES

1. Harry CL, Stephen NO,et al. Coronary In-Stent Restenosis: Current Status and Future Strategies. Journal of the Amerian College of Cardiology 2002;39:183-191.

2. Mehilli J, Kastrati A, et al. Intracoronary Stenting and Angiographic Results. Catheterization and Cardiovascular Interventions 2004;61:190-195.

3. Grube E, Silber S et al. TAXUS I. Six-and Twelve Month Results from a Randomized, double-blind trial on a Slow-Relase Paclitaxel-Eluting Stent for de novo coronary lesions. Circulation 2003;107:38-42.

4. Tanabe K, Serruys PW et al. TAXUS III Trial. In-Stent restenosis treated with stent-based delivery of Pclitaxel incorporated en a slow-relase polymer formulation. Circulation 2003;107:559-564.

5. Park SJ, Shim WH et al. A Paclitaxel-Eluting stent for the preventiion of coronary restenosis. The New England Journal of Medicine 2003;348:1537-1544.

6. Herdeg Ch, Oberhoff M et al. Local Paclitaxel Delivery for the prevention of restenosis: Biological effects and efficacy in vivo. Journal of the American College of Cardiology 2000;35:1969-1976.

7. Carter AJ. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheterization and Cardiovascular interventions 2004;61:233-236.

8. Serruys PW, Kay IP et al. Periprocedural quantitative coronary angiography after Palmaz Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the Belgian Netherlands Stent study ( BENESTENT ) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999;34: 1067-1074.

9. Liistro F, Stankovic G et al. First Clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis. Circulation 2002;105:1883-1886.

10. Kong DK, Eisenstein EL. Economic impact of drug-eluting stents on hospital systems: A disease-state model. American Heart Journal 2004;147:449-456

11. The Porcine Coronary Model of in stent restenosis: current status in the era of drug-eluting stents. Catheterization and Cardiovascular interven-tions;60:515-523

12. Mezeika P, Prasad N et al. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. American Heart Journal 2004;145:1013-1021

13. Farb A, Heller PF et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.

14. Axel DI, Kunert W et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645.